Efgartigimod for Consolidation Therapy in gMG

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

NCT06298565 ·Status: RECRUITING

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170 ·Status: RECRUITING

Pre-Approval Access for Efgartigimod PH20 SC in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT04777734 ·Status: AVAILABLE

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis

NCT04818671 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

NCT00727194 ·Status: TERMINATED ·Phase: PHASE2

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

NCT07072988 ·Status: RECRUITING ·Phase: PHASE4

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis

NCT04735432 ·Status: COMPLETED ·Phase: PHASE3

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916 ·Status: RECRUITING ·Phase: PHASE3

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295 ·Status: TERMINATED ·Phase: PHASE2

Clinical Prognosis and Progression of Myasthenia Gravis Patients

NCT04101578 ·Status: UNKNOWN

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

NCT06765161 ·Status: RECRUITING ·Phase: PHASE3

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539 ·Status: COMPLETED

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

NCT06827587 ·Status: NOT_YET_RECRUITING ·Phase: NA

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients ：a Prospective Observational Study

NCT04941079 ·Status: UNKNOWN

A Prospective Cohort Study Of Myasthenia Gravis

NCT04674605 ·Status: UNKNOWN

Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment

NCT06381284 ·Status: COMPLETED

A Prospective Cohort Study of Myasthenia Gravis in China

NCT06006832 ·Status: RECRUITING

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

NCT07217587 ·Status: RECRUITING ·Phase: PHASE3